

A multicentre randomised trial of short neo-adjuvant chemotherapy (VAPEC-B) plus involved field radiotherapy (MIT) versus mantle radiotherapy

Submission date 01/07/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 01/07/2001	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 17/02/2015	Condition category Cancer	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

--

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00002987

Protocol serial number

LY07

Study information

Scientific Title

A multicentre randomised trial of short neo-adjuvant chemotherapy (VAPEC-B) plus involved field radiotherapy (MIT) versus mantle radiotherapy

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Lung (non-small cell) cancer

Interventions

1. VAPEC-B regimen: minimal initial chemotherapy therapy involving vincristine, adriamycin, etoposide, cyclophosphamide and bleomycin, followed by involved field radiotherapy
2. Control regimen: mantle radiotherapy

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Vincristine, adriamycin, etoposide, cyclophosphamide and bleomycin

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

26/06/2001

Eligibility

Key inclusion criteria

1. Patients aged between 16 and 75 years
2. Histologically proven Hodgkin's disease, stage IA or IIA with no mediastinal bulk
3. No previous treatment
4. No previous malignancy other than basal cell carcinoma or cervical intra-epithelial neoplasms
5. No concurrent illness which would contraindicate chemotherapy or radiotherapy
6. Not documented evidence of Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

If Hodgkin's disease is below the diaphragm only, patients are not eligible for this trial

Date of first enrolment

01/01/1995

Date of final enrolment

26/06/2001

Locations

Countries of recruitment

United Kingdom

Study participating centre

-

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results	abstract A-E08, 39	07/09/2004		No	No